Advertisement

The use of 18F-FDG PET ratios in the differential diagnosis of common malignant brain tumors

      Abstract

      Objective

      This study examined the use of positron emission tomography (PET) ratios to improve the diagnostic ability of 18F-FDG PET/computed tomography (CT) in the differentiation of enhancing brain metastases, central nervous system lymphomas, and gliomas.

      Materials and methods

      Seventy-six patients with malignant brain tumors and available magnetic resonance imaging and PET/CT examinations were included.

      Results

      Among standardized uptake value (SUV)-related parameters tested, tumor maximum SUV to ipsilateral cortex maximum SUV ratio (Tmax:WMimax) and maximum SUV (SUVmax) proved to be the two most valuable parameters for differential diagnosis.

      Conclusion

      In addition to SUVmax, Tmax:WMimax also seems to provide helpful information for the differential diagnosis of lymphomas from other malignant brain tumors.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Imaging
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bulakbasi N
        • Kocaoglu M
        • Ors F
        • Tayfun C
        • Ucoz T
        Combination of single-voxel proton MR spectroscopy and apparent diffusion coefficient calculation in the evaluation of common brain tumors.
        AJNR Am J Neuroradiol. 2003; 24: 225-233
        • Calli C
        • Kitis O
        • Yunten N
        • Yurtseven T
        • Islekel S
        • Akalin T
        Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors.
        Eur J Radiol. 2006; 58: 394-403
        • Kosaka N
        • Tsuchida T
        • Uematsu H
        • Kimura H
        • Okazawa H
        • Itoh H
        18F-FDG PET of common enhancing malignant brain tumors.
        AJR Am J Roentgenol. 2008; 190: W365-W369
        • Barker FG
        • Chang SM
        • Valk PE
        • Pounds TR
        • Prados MD
        18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma.
        Cancer. 1997; 79: 115-126
        • Delbeke D
        • Meyerowitz C
        • Lapidus RL
        • Maciunas RJ
        • Jennings MT
        • Moots PL
        • et al.
        Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET.
        Radiology. 1995; 195: 47-52
        • Palmedo H
        • Urbach H
        • Bender H
        • Schlegel U
        • Schmidt-Wolf IG
        • Matthies A
        • et al.
        FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up.
        Eur J Nucl Med Mol Imaging. 2006; 33: 164-168
        • Charnley N
        • West CM
        • Barnett CM
        • Brock C
        • Bydder GM
        • Glaser M
        • et al.
        Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy.
        Int J Radiat Oncol Biol Phys. 2006; 66: 331-338
        • Kim YH
        • Oh SW
        • Lim YJ
        • Park CK
        • Lee SH
        • Kang KW
        • et al.
        Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI.
        Clin Neurol Neurosurg. 2010; 112: 758-765
        • Dhermain FG
        • Hau P
        • Lanfermann H
        • Jacobs AH
        • van den Bent MJ
        Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas.
        Lancet Neurol. 2010; 9: 906-920
        • Spaeth N
        • Wyss MT
        • Weber B
        • Scheidegger S
        • Lutz A
        • Verwey J
        • et al.
        Uptake of 18F-fluorocholine, 18F-fluoroethyl-L-tyrosine, and 18F-FDG in acute cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumor recurrence.
        J Nucl Med. 2004; 45: 1931-1938
        • Tsuyuguchi N
        • Takami T
        • Sunada I
        • Iwai Y
        • Yamanaka K
        • Tanaka K
        • et al.
        Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery in malignant glioma.
        Ann Nucl Med. 2004; 18: 291-296
        • Van Laere K
        • Ceyssens S
        • Van Calenbergh F
        • de Groot T
        • Menten J
        • Flamen P
        • et al.
        Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value.
        Eur J Nucl Med Mol Imaging. 2005; 32: 39-51
        • Makino K
        • Hirai T
        • Nakamura H
        • Murakami R
        • Kitajima M
        • Shigematsu Y
        • et al.
        Does adding FDG-PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study.
        Ann Nucl Med. 2011; 25: 432-438
        • Heiss WD
        • Raab P
        • Lanfermann H
        Multimodality assessment of brain tumors and tumor recurrence.
        J Nucl Med. 2011; 52: 1585-1600
        • Benard F
        • Romsa J
        • Hustinx R
        Imaging gliomas with positron emission tomography and single-photon emission computed tomography.
        Semin Nucl Med. 2003; 33: 148-162
        • Hustinx R
        • Smith RJ
        • Benard F
        • Bhatnagar A
        • Alavi A
        Can the standardized uptake value characterize primary brain tumors on FDG-PET?.
        Eur J Nucl Med. 1999; 26: 1501-1509
        • Hamberg LM
        • Hunter GJ
        • Alpert NM
        • Choi NC
        • Babich JW
        • Fischman AJ
        The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification?.
        J Nucl Med. 1994; 35: 1308-1312
        • O'Doherty MJ
        • Barrington SF
        • Campbell M
        • Lowe J
        • Bradbeer CS
        PET scanning and the human immunodeficiency virus-positive patient.
        J Nucl Med. 1997; 38: 1575-1583
        • Villringer K
        • Jager H
        • Dichgans M
        • Ziegler S
        • Poppinger J
        • Herz M
        • et al.
        Differential diagnosis of CNS lesions in AIDS patients by FDG-PET.
        J Comput Assist Tomogr. 1995; 19: 532-536
        • Hoffman JM
        • Waskin HA
        • Schifter T
        • Hanson MW
        • Gray L
        • Rosenfeld S
        • et al.
        FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS.
        J Nucl Med. 1993; 34: 567-575
        • Kuwabara Y
        • Ichiya Y
        • Otsuka M
        • Miyake Y
        • Gunasekera R
        • Hasuo K
        • et al.
        High [18F]FDG uptake in primary cerebral lymphoma: a PET study.
        J Comput Assist Tomogr. 1988; 12: 47-48
        • Maza S
        • Buchert R
        • Brenner W
        • Munz DL
        • Thiel E
        • Korfel A
        • et al.
        Brain and whole-body FDG-PET in diagnosis, treatment monitoring and long-term follow-up of primary CNS lymphoma.
        Radiol Oncol. 2013; 47: 103-110
        • Zukotynski K
        • Fahey F
        • Kocak M
        • Kun L
        • Boyett J
        • Fouladi M
        • et al.
        18F-FDG PET and MR imaging associations across a spectrum of pediatric brain tumors: a report from the pediatric brain tumor consortium.
        J Nucl Med. 2014; 55: 1473-1480
        • Rosenfeld SS
        • Hoffman JM
        • Coleman RE
        • Glantz MJ
        • Hanson MW
        • Schold SC
        Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography.
        J Nucl Med. 1992; 33: 532-536